COMPANY PROFILE

Anticancer Bioscience

Explore full profile

Dedicated to the development of synthetic lethal therapies that address unmet medical needs

Chengdu, ChinaFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Anticancer Bioscience

Anticancer Bioscience is an international precision oncology company focused on developing targeted cancer therapies through synthetic lethal approaches. The company leverages discoveries from the J. Michael Bishop Institute of Cancer Research to identify novel compounds that target genetic and epigenetic vulnerabilities in cancer cells. Anticancer Bioscience operates in the biotechnology and pharmaceutical markets, serving healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around translating basic research breakthroughs into clinical assets, which are then commercialized. Revenue is generated through the development and licensing of proprietary cancer therapeutics and drug delivery technologies. The company benefits from exclusive pipeline agreements and patents transferred from the J. Michael Bishop Institute, ensuring a steady flow of innovative cancer treatment solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Chengdu, China
Employees: 17
Open positions: None listed
Dealroom signal: 46.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Oct 2021	$11M	$55M	3 Rivers Capital	—
SEED✓Equity / VC	Feb 2021	$10M	$55M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Anticancer Bioscience website traffic

Latest recorded traffic for Anticancer Bioscience is 2.5K monthly website visits, up 8233.3% over the last three months. Anticancer Bioscience's team grew 13.3% over the past year.

Latest monthly visits2.5K 3-month web change+8233.3% 1-year team growth+13.3%

Monthly website visitsAug 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OHOssium HealthBuilding the world's first bone marrow bank to treat blood cancers	San Francisco, United States	Operational	104	$135M	$315M
SCScreenCellA provider of rare cell isolation solutions for medical and research applications	Paris, France	Operational
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational
BBBiond BiologicsInnovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients	Misgav Am, Israel	Operational
RTRTsafeEnsures safety and efficiency of radiation oncology treatments of cancer patients, in a personalized (patient-specific) manner	Athens, Greece	Operational
ABAkamis BioLeading company in developing cancer gene therapies	Abingdon, United Kingdom	Operational
ATAvila TherapeuticsFocused on the development of covalent drugs to treat cancer and other autoimmune diseases	Waltham, United States	Acquired
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational